Keel Point LLC Sells 9,252 Shares of Merck & Co., Inc. $MRK

Keel Point LLC lessened its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 15.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 51,571 shares of the company’s stock after selling 9,252 shares during the quarter. Keel Point LLC’s holdings in Merck & Co., Inc. were worth $5,428,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of MRK. Chesapeake Wealth Management raised its holdings in Merck & Co., Inc. by 0.6% during the 4th quarter. Chesapeake Wealth Management now owns 14,740 shares of the company’s stock valued at $1,552,000 after acquiring an additional 87 shares during the period. Syverson Strege & Co raised its holdings in Merck & Co., Inc. by 2.2% during the 4th quarter. Syverson Strege & Co now owns 4,142 shares of the company’s stock valued at $436,000 after acquiring an additional 90 shares during the period. Westside Investment Management Inc. raised its holdings in Merck & Co., Inc. by 3.1% during the 4th quarter. Westside Investment Management Inc. now owns 3,142 shares of the company’s stock valued at $331,000 after acquiring an additional 93 shares during the period. Valued Wealth Advisors LLC raised its holdings in Merck & Co., Inc. by 26.9% during the 4th quarter. Valued Wealth Advisors LLC now owns 444 shares of the company’s stock valued at $47,000 after acquiring an additional 94 shares during the period. Finally, Intrua Financial LLC raised its holdings in Merck & Co., Inc. by 1.1% during the 4th quarter. Intrua Financial LLC now owns 8,604 shares of the company’s stock valued at $906,000 after acquiring an additional 96 shares during the period. Institutional investors own 76.07% of the company’s stock.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck Animal Health announced a definitive agreement to acquire TARGAN, adding a biodevice company focused on poultry performance and strengthening Merck’s animal health growth platform. Merck Animal Health to Acquire TARGAN
• Positive Sentiment: MRK regained its 50-day moving average and remains above its 200-day trendline, with articles pointing to Keytruda growth, pipeline advances, and recent deals as supporting factors. Merck Stock Moves Above 50-Day SMA: Assessing Its Investment Case
• Positive Sentiment: Wells Fargo reiterated its Buy rating on Merck, reinforcing a constructive analyst view on the stock. Wells Fargo Keeps Their Buy Rating on Merck & Company (MRK)
• Neutral Sentiment: Recent “most searched stocks” and market commentary indicate rising investor attention, but do not point to a specific new fundamental development for MRK. Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
• Neutral Sentiment: Broader healthcare-dealmaking momentum may be supportive for sector sentiment, but it is an indirect driver for Merck rather than a company-specific catalyst. Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines
• Neutral Sentiment: Articles highlighting Merck’s recent outperformance versus its moving averages and strong Keytruda franchise are supportive, but largely reflect ongoing investor optimism rather than a new surprise. Merck Stock Moves Above 50-Day SMA: Assessing Its Investment Case
• Negative Sentiment: One market note said Merck rose but still lagged the broader market, implying investors may be favoring faster-moving names elsewhere despite MRK’s gains. Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Merck & Co., Inc. Stock Up 1.4%

MRK opened at $120.81 on Friday. The stock has a market cap of $298.37 billion, a PE ratio of 34.03, a P/E/G ratio of 2.68 and a beta of 0.21. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a 52 week low of $76.66 and a 52 week high of $125.14. The business’s fifty day simple moving average is $116.59 and its 200 day simple moving average is $113.19.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to analysts’ expectations of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm’s revenue was up 4.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, research analysts expect that Merck & Co., Inc. will post 5.17 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be paid a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio is currently 95.77%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on MRK. Wall Street Zen raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Saturday, June 6th. Citigroup began coverage on shares of Merck & Co., Inc. in a report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 target price on the stock. Barclays began coverage on shares of Merck & Co., Inc. in a report on Friday, February 20th. They set an “overweight” rating and a $140.00 target price on the stock. Royal Bank Of Canada reissued an “outperform” rating and set a $142.00 target price on shares of Merck & Co., Inc. in a report on Monday, March 30th. Finally, Zacks Research raised shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and a consensus target price of $128.18.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.